Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.
about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationThe safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic reviewThe relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.Systemic safety of anti-VEGF drugs: a commentary.Diabetic retinopathy: pathogenesis, clinical grading, management and future developments.Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis.Current treatments in diabetic macular oedema: systematic review and meta-analysisSubretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.Analysis of Potential Ischemic Effect of Intravitreal Bevacizumab on Unaffected Retina in Treatment-Naïve Macular Edema Due to Branch Retinal Vein Occlusion: A Prospective, Interventional Case-SeriesRelief Effect of Bevacizumab on Severe Edema Induced by Re-irradiation in Brain Tumor PatientsTherapeutic potential of intravitreal pharmacotherapy in retinal vein occlusionTreatments for macular oedema following central retinal vein occlusion: systematic review.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.A safety evaluation of ranibizumab in the treatment of age-related macular degeneration.Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario.Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System.Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.Current and Future Techniques in Wound Healing Modulation after Glaucoma Filtering SurgeriesUnilateral branch retinal arterial occlusion following administration of bevacizumab for branch retinal vein occlusion.Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study.Systemic effects after intravitreal injection of bevacizumab in new born rabbit eyes.Adverse gastrointestinal events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration.The association between myocardial infarction and intravitreal bevacizumab injection.Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
P2860
Q24193614-2E8711C6-782F-4052-8B25-8A6E07700038Q27013836-9BC432E7-7390-4B20-B90C-D3783232C014Q34378757-FEA06910-F763-44B4-9C74-50FF3BCA35E9Q34444212-D3202CF3-0AE6-455F-AFC9-59D8800425B0Q34452811-AFF4EEA1-2824-401E-8B1A-0BB7855F238FQ34498235-0479C379-36E7-4255-8668-14DFDA4BAFF6Q34567356-F8981A29-2D3E-490B-B8E3-180BC161652EQ34606190-2596199E-9BD0-4D5A-9A4A-44814F6C8632Q35896048-87CD8361-E5AA-4860-83A2-1039C8DBB31DQ36130147-6585EA4D-3A9A-4CB1-B8B3-507586AD29FAQ36477223-C277CCCE-FBFA-4C43-B369-D2847272B2F4Q36490483-05095FD8-025C-4CCB-B83F-411D11282EE3Q37590692-F83F1E7D-326B-4F0B-8135-AA35DFA04453Q38210239-52A57455-D01A-4555-96D9-8B05AAD94633Q38236770-7D0F627C-C637-4442-9E55-0C640DF2405DQ38261105-EADAA5FD-F6EB-41C5-8EB1-18777088F06BQ38671399-73845E94-ADCF-4723-B054-689C9648211FQ38741548-F4EDF057-4DFA-4F6D-BF45-1E8A715E7730Q38764072-5D93AD3B-A7A5-42D2-AAB0-DA6E781BCC99Q38788689-A5D0F017-8796-4068-BEA4-1D3DE89AA367Q44205884-A982B655-288F-433D-9E4B-46385A5E5E64Q46758670-34FFEA13-1FAE-4B0C-A20C-7DC5EC0A40CDQ48018646-7735B211-3C91-4413-BED0-A53C60C00DFFQ50164526-416C7031-F17C-4831-8313-615F7F31BB10Q50903375-FD971236-7BF6-42A2-93B0-73FE976A96E2Q55122457-79021588-D80E-4BAE-A8D7-2166DC4239D5Q58804239-C09BEB03-324F-47E5-8EBB-57844BD58BB9
P2860
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Adverse events with intravitre ...... rs: nested case-control study.
@ast
Adverse events with intravitre ...... rs: nested case-control study.
@en
type
label
Adverse events with intravitre ...... rs: nested case-control study.
@ast
Adverse events with intravitre ...... rs: nested case-control study.
@en
prefLabel
Adverse events with intravitre ...... rs: nested case-control study.
@ast
Adverse events with intravitre ...... rs: nested case-control study.
@en
P2093
P2860
P356
P1433
P1476
Adverse events with intravitre ...... ors: nested case-control study
@en
P2093
J Michael Paterson
Marlo Whitehead
Robert J Campbell
Sudeep S Gill
Susan E Bronskill
P2860
P356
10.1136/BMJ.E4203
P407
P50
P577
2012-07-04T00:00:00Z